How Skyrizi Works for Psoriatic Arthritis

Skyrizi (risankizumab) is a humanized monoclonal antibody that works by inhibiting the interleukin-23 (IL-23) cytokine, which plays a key role in the inflammation and joint damage associated with psoriatic arthritis (PsA). Here's how Skyrizi works:

Binds to IL-23: Skyrizi binds specifically to IL-23, a pro-inflammatory cytokine that is involved in the pathogenesis of PsA. IL-23 is produced by immune cells such as macrophages and dendritic cells, and it promotes the differentiation and activation of T helper 17 (Th17) cells, which are involved in the inflammatory process in PsA.

Neutralizes IL-23 activity: By binding to IL-23, Skyrizi prevents it from interacting with its receptor, the IL-23 receptor, which is expressed on immune cells. This prevents the downstream signaling pathways that are triggered by IL-23, including the activation of Th17 cells and the production of inflammatory cytokines.

Reduces inflammation: By neutralizing IL-23, Skyrizi reduces inflammation in the joints and skin affected by PsA. This leads to improvements in symptoms such as joint pain, stiffness, swelling, and skin lesions.

Suppresses disease activity: Over time, Skyrizi can suppress disease activity in PsA by reducing the number of active inflammatory lesions, improving joint function, and slowing the progression of joint damage.

It's important to note that Skyrizi is usually given by injection, and the dosing schedule and duration of treatment may vary depending on individual patient needs and response to the medication. It should be used under the guidance and supervision of a healthcare provider who has experience in managing PsA.